CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL

[1]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[2]  R. Orentas,et al.  Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  M. Sabatino,et al.  Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells , 2017, Journal of Translational Medicine.

[4]  Syed Abbas Ali,et al.  T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. , 2016, Blood.

[5]  J. Khan,et al.  CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity , 2016, Nature Communications.

[6]  Hao Liu,et al.  Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. , 2016, The Journal of clinical investigation.

[7]  M. Sabatino,et al.  Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. , 2016, Cytotherapy.

[8]  M. Liedtke,et al.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.

[9]  D. Maloney,et al.  Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. , 2016, Blood.

[10]  P. Lähteenmäki,et al.  Health conditions associated with metabolic syndrome after cancer at a young age: A nationwide register-based study. , 2016, Cancer epidemiology.

[11]  W. Han,et al.  CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma , 2016 .

[12]  Brian Keith,et al.  Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. , 2016, Immunity.

[13]  M. McGranaghan,et al.  Progress through collaboration. , 2016, The bone & joint journal.

[14]  D. Teachey,et al.  Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019) , 2015 .

[15]  T. Fry,et al.  Preclinical Development of Bispecific Chimeric Antigen Receptor Targeting Both CD19 and CD22 , 2015 .

[16]  David Allman,et al.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. , 2015, Cancer discovery.

[17]  A. Heimberger,et al.  Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. , 2015, Cancer research.

[18]  J. Downing,et al.  Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Loh,et al.  Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. , 2015, Blood.

[20]  Xiaomin Lu,et al.  Re‐induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2 , 2015, Pediatric blood & cancer.

[21]  I. Pastan,et al.  Characterization of CD22 expression in acute lymphoblastic leukemia , 2015, Pediatric blood & cancer.

[22]  J. Downing,et al.  Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. , 2015, The Lancet. Oncology.

[23]  R. Kaplan,et al.  4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors , 2015, Nature Medicine.

[24]  H. Dombret,et al.  Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study , 2015, Haematologica.

[25]  S. Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[26]  T. Naoe,et al.  Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+ T Cells , 2015, The Journal of Immunology.

[27]  Albrecht Reichle,et al.  Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Konopleva,et al.  Augmented Berlin‐Frankfurt‐Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) , 2014, Cancer.

[29]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[30]  S. Altekruse,et al.  Declining childhood and adolescent cancer mortality , 2014, Cancer.

[31]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[32]  P. Nathan,et al.  Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort. , 2014, The Lancet. Oncology.

[33]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[34]  G. Marti,et al.  Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia. , 2013, American journal of clinical pathology.

[35]  A. Scott,et al.  Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  Jeffrey A Jones,et al.  A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701 , 2013, Cancer.

[37]  H. Kantarjian,et al.  Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia , 2013, Cancer.

[38]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[39]  N. Fox,et al.  Cognition assessment using the NIH Toolbox , 2013, Neurology.

[40]  I. Pastan,et al.  Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. , 2013, Blood.

[41]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[42]  W. Wilson,et al.  Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  L. Vidal,et al.  Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric‐inspired regimens: Systematic review and meta‐analysis , 2012, American journal of hematology.

[44]  Jinjuan Wang,et al.  CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. , 2012, Blood.

[45]  H. Kantarjian,et al.  Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. , 2012, The Lancet. Oncology.

[46]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[47]  Hermann Einsele,et al.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. Foà,et al.  Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases , 2011, Leukemia & lymphoma.

[49]  G. Marti,et al.  Variables affecting the quantitation of CD22 in neoplastic B cells , 2011, Cytometry. Part B, Clinical cytometry.

[50]  S. Steinberg,et al.  Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial , 2010, Clinical Cancer Research.

[51]  Mitchell Ho,et al.  Identification and characterization of fully human anti-CD22 monoclonal antibodies , 2009, mAbs.

[52]  P. Chevallier,et al.  Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases , 2009, Leukemia.

[53]  M. Loh,et al.  Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study , 2008, Leukemia.

[54]  S. Canevari,et al.  Redirected Activity of Human Antitumor Chimeric Immune Receptors is Governed by Antigen and Receptor Expression Levels and Affinity of Interaction , 2007, Journal of immunotherapy.

[55]  M. Czuczman,et al.  A Quantitative Exploration of Surface Antigen Expression in Common B-Cell Malignancies Using Flow Cytometry , 2006, Immunological investigations.

[56]  A. Órfão,et al.  BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. , 2001, Leukemia.

[57]  H. Niitani,et al.  [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[58]  R. Echols,et al.  in a Phase 2 Study , 2019 .

[59]  G. Armstrong,et al.  Temporal patterns in the risk of chronic health conditions among survivors of childhood cancer diagnosed 1970-1999: a report from the Childhood Cancer Survivor Study cohort , 2018 .

[60]  D. Waitzberg,et al.  Prospective Study , 2020, Encyclopedia of Behavioral Medicine.

[61]  R. Larson,et al.  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. , 2015, The Lancet. Oncology.

[62]  C. Pui,et al.  Concepts and Strategies , 2010 .

[63]  R. Arceci,et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study , 2009 .

[64]  A. Órfão,et al.  BIOMED-1 concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings , 2001, Leukemia.